アメリカの癌生検の市場規模は、2028年までに159億8,000万USドルに達する見込みです。2021年から2028年までのCAGRは11.0%で拡大すると予想されています。病気の早期発見のために技術的に優れた機器の使用が増えていることが、市場を牽引する重要な要因の一つです。
この市場では、腫瘍からリキッドバイオプシーへの重要なトランザクションによって、この技術の採用が進むと予想されます。この傾向を認識して、いくつかの事業体は、生検キットのポートフォリオを拡大するために様々な取り組みを行っています。例えば、2021年6月には、Biocept, Inc.社とQuest Diagnostics社が共同で、肺癌診断のためのNGSベースのリキッドバイオプシー検査を提供しています。
さらに、国内の規制や償還に関する支援策が市場の成長を支えています。アメリカのFDAは、癌生検製品の商業化を支援し、臨床現場でのこれらのアッセイの使用を増やすことに積極的に取り組んでいます。例えば、2021年3月、アメリカのFDAは、早期癌の残存疾患を最小限に抑えるためのリキッドバイオプシーアッセイであるRaDaRに画期的なデバイスとしての指定を与えました。
目次
Table of Contents
Chapter 1 Methodology And Scope
1.1 Research Methodology
1.2 Research Assumptions
1.2.1 Estimates and forecast timeline
1.3 Research Methodology
1.4 Information Procurement
1.4.1 Purchased database
1.4.2 GVR’s internal database
1.4.3 Secondary sources
1.4.3.1 Primary research
1.4.4 Details of primary research
1.5 Information or Data Analysis
1.5.1 Data analysis models
1.5.1.1 End - use landscape assessment
1.5.1.2 Market origin assessment
1.5.1.3 Oncology diagnosis: market competition analysis
1.6 Market Formulation and Validation
1.7 Model Details
1.7.1 Commodity Flow Analysis
1.7.1.1 Approach 1: Commodity flow approach
1.7.1.2 Approach 2: Country - wise market estimation using bottom - up approach
1.8 U.S. Market: CAGR Calculation
1.9 List of Secondary Sources
1.10 List of Primary Sources
Chapter 2 Executive Summary
Chapter 3 Market Variables, Trends, And Scope
3.1 Cancer Medical Tourism Within & Outside the U.S.
3.2 Market Driver Analysis
3.2.1 Advent of liquid biopsy
3.2.2 Transition of novel oncology diagnostics from bench to clinics
3.2.3 Advancements in quality and payment pertaining to genetic cancer tests
3.3 Market Restraint Analysis
3.3.1 Risks associated with biopsy procedures
3.3.2 Technical and clinical challenges
3.4 Market Opportunity Analysis
3.4.1 Integral role of biopsies in oncology companion diagnostics
3.4.2 Increase in the demand for biopsies in translational research
3.5 Market Threat Analysis
3.5.1 Risk associated with repeat biopsy procedures
Chapter 4 Business Environment Analysis
4.1 SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)
4.2 Porter’s Five Forces Analysis
Chapter 5 Supply Chain Analysis
5.1 Sample Collection (List of biobanks/center)
5.2 Sample Processing (List of vendors)
Chapter 6 Cost/ Pricing Analysis
6.1 Biopsy Cost
6.1.1 By Indication
6.1.1.1 Typical biopsy costs for patients not covered by health insurance, U.S.
6.1.2 By Type/Method
6.2 Key Factors Influencing the Cost
6.3 Costs of Cancer Management
6.3.1 Pharma versus diagnostics price analysis for cancer care
6.3.2 U.S. Expenditures for cancer by source of payment
6.3.2.1 expenditures for cancer care by year & cancer site, USD Million, 2010 - 2018
Chapter 7 Reimbursement & Regulatory Analysis
7.1 Regulatory Framework: U.S. Cancer Biopsy Market
7.2 Reimbursement Framework: U.S. Cancer Biopsy Market
Chapter 8 Challenges/Restraints/Complications Analysis
8.1 Challenges/Restraints/Complications Analysis
8.1.1 By site (organ)
8.1.2 By method
Chapter 9 U.S. Cancer Biopsy Market: Type Business Analysis
9.1 Market: Type Movement Analysis
9.2 Market: Comparative Analysis of Biopsy Type
9.3 Fine - Needle Aspiration
9.3.1 Market estimates and forecasts, 2017 - 2028 (USD Million)
9.3.1.1 Market estimates and forecasts for pharma - use, 2017 - 2028 (USD Million)
9.3.1.2 Market estimates and forecasts for clinical - use, 2017 - 2028 (USD Million)
9.4 Core Needle Biopsy (CNB)
9.4.1 Market estimates and forecasts, 2017 - 2028 (USD Million)
9.4.1.1 Market estimates and forecasts for pharma - use, 2017 - 2028 (USD Million)
9.4.1.2 Market estimates and forecasts for clinical - use, 2017 - 2028 (USD Million)
9.5 Cancer Surgical Biopsy
9.5.1 Market estimates and forecasts, 2017 - 2028 (USD Million)
9.5.1.1 Market estimates and forecasts for pharma - use, 2017 - 2028 (USD Million)
9.5.1.2 Market estimates and forecasts for clinical - use, 2017 - 2028 (USD Million)
9.6 Skin Biopsy /Punch Biopsy
9.6.1 Market estimates and forecasts, 2017 - 2028 (USD Million)
9.6.1.1 Market estimates and forecasts for pharma - use, 2017 - 2028 (USD Million)
9.6.1.2 Market estimates and forecasts for clinical - use, 2017 - 2028 (USD Million)
9.7 Others
9.7.1 Market estimates and forecasts for other types, 2017 - 2028 (USD Million)
9.7.1.1 Market estimates and forecasts for pharma - use, 2017 - 2028 (USD Million)
9.7.1.2 Market estimates and forecasts for clinical - use, 2017 - 2028 (USD Million)
Chapter 10 U.S. Cancer Biopsy Market: Site (Organ) Business Analysis
10.1 Market: Site (Organ) Movement Analysis
10.2 Breast
10.2.1 Market estimates and forecasts for breast, 2017 - 2028 (USD Million)
10.3 Thyroid
10.3.1 Market estimates and forecasts for thyroid, 2017 - 2028 (USD Million)
10.4 Uterus & Cervix
10.4.1 Market estimates and forecasts for uterus & cervix, 2017 - 2028 (USD Million)
10.5 Lung
10.5.1 Market estimates and forecasts for lung, 2017 - 2028 (USD Million)
10.6 Prostate
10.6.1 Market estimates and forecasts for prostate, 2017 - 2028 (USD Million)
10.7 Bladder
10.7.1 Market estimates and forecasts for bladder, 2017 - 2028 (USD Million)
10.8 Kidney
10.8.1 Market estimates and forecasts for kidney, 2017 - 2028 (USD Million)
10.9 Liver
10.9.1 Market estimates and forecasts for liver, 2017 - 2028 (USD Million)
10.10 Pancreas
10.10.1 Market estimates and forecasts for pancreas, 2017 - 2028 (USD Million)
10.11 Other Sites
10.11.1 Market estimates and forecasts for other sites, 2017 - 2028 (USD Million)
Chapter 11 U.S. Cancer Biopsy Market: Application Business Analysis
11.1 Market: Application Movement Analysis
11.2 Screening & Monitoring
11.2.1 Market estimates and forecasts for screening & monitoring, 2017 - 2028 (USD Million)
11.3 Diagnostics
11.3.1 Market estimates and forecasts for diagnostics, 2017 - 2028 (USD Million)
11.4 Investigational & Translational Research
11.4.1 Market estimates and forecasts for investigational & translational research, 2017 - 2028 (USD Million)
11.5 Pharma & Biopharma Discovery & Development
11.5.1 Market estimates and forecasts for pharma & biopharma discovery & development, 2017 - 2028 (USD Million)
Chapter 12 Company Profiles
12.1 Company Profiles
12.1.1 BD (Becton, Dickinson and Company)
12.1.1.1 Company overview
12.1.1.2 Financial performance
12.1.1.3 Product benchmarking
12.1.1.4 Strategic initiatives
12.1.2 IZI Medical Products
12.1.2.1 Company overview
12.1.2.2 Product benchmarking
12.1.2.3 Strategic initiatives
12.1.3 Johnson & Johnson Services
12.1.3.1 Company overview
12.1.3.2 DePuy Synthes
12.1.3.2.1 Company overview
12.1.3.3 Ethicon, Inc.
12.1.3.3.1 Company overview
12.1.3.4 Financial performance
12.1.3.5 Product benchmarking
12.1.4 Argon Medical
12.1.4.1 Company overview
12.1.4.2 Product benchmarking
12.1.5 Cook Medical
12.1.5.4 Company overview
12.1.5.5 Product benchmarking
12.1.6 Spectra Medical Devices, Inc.
12.1.6.1 Company overview
12.1.6.2 Product benchmarking
12.1.7 Medtronic plc
12.1.7.1 Company overview
12.1.7.2 Financial performance
12.1.7.3 Product benchmarking
12.1.8 Boston Scientific Corporations
12.1.8.1 Company overview
12.1.8.2 Financial performance
12.1.8.3 Product benchmarking
12.1.8.4 Strategic initiatives
12.1.9 Conmed Corporation
12.1.9.1 Company overview
12.1.9.2 Financial performance
12.1.9.3 Product benchmarking
12.1.10 Inrad, Inc.
12.1.10.1 Company overview
12.1.10.2 Product benchmarking
